

Investing in America's Health

Researching, Developing and Manufacturing Innovative Medicines across the United States

Novartis is investing \$23 billion to expand our US manufacturing and R&D presence. We're breaking new ground nationwide and building a resilient, future-ready supply chain to deliver meaningful impact for people and society.

US Investment Fast Facts



\$23B

Investment in manufacturing, research and technology



7

Number of new facilities



3

Number of expanded facilities



~1,000

New Novartis jobs expected to be created, plus 4,000 indirect jobs across the US supply chain



3

Advanced technology platforms manufactured in the US (radioligand, RNA and cell and gene therapies)




4

Core therapeutic areas with US manufacturing capacity (oncology, immunology, neuroscience, and cardiovascular, renal and metabolic)

Expanding Our US Footprint for US Patients

Novartis is expanding coast to coast with facilities from New Jersey to Texas and California. We are on track to localize 100% of production of our key medicines for US patients in the US.



Investing in America's Health

Coast-to-Coast Manufacturing and R&D

Each site is a hub of innovation and talent, built to unlock new treatments and advance breakthrough medicines. The coast-to-coast network brings therapies closer to patients and powers progress in communities nationwide.



Biomedical Research Centers

Providing world-class scientific infrastructure and drug-discovery capabilities to scale innovation and deliver meaningful breakthroughs for patients

San Diego, CA

Once operational in 2029, the new center will provide world-class scientific infrastructure and drug-discovery capabilities, building on 25+ years of Novartis R&D in San Diego.

Cambridge, MA

Established as a global hub for the Biomedical Research organization in 2003, the site is home to cutting-edge research facilities dedicated to scientific innovation and drug discovery.



Flagship Manufacturing Hub in North Carolina

Creating an end-to-end manufacturing infrastructure across oncology, immunology, neuroscience, and cardiovascular, renal and metabolic

Small molecule, RNA production in Morrisville

One facility will produce and package solid dosage tablets and capsules. A second will manufacture active pharmaceutical ingredients for solid dosage tablets, capsules and RNA treatments.

Biologics production in Durham

The new Durham site will have two facilities for manufacturing biologics and sterile packaging, including a large-scale cell culture facility.

Gene therapy production in Durham

The first Durham site makes gene therapies, as well as gene therapy products for clinical trials.



Radioligand Therapy (RLT) Manufacturing Network

Helping ensure cancer patients can receive time-sensitive, personalized RLT, a form of precision medicine that delivers radiation directly to cancer cells

Denton, TX

Expected to become operational in 2028, the new RLT site will support jobs in bioengineering, advanced manufacturing, quality and operations.

Winter Park, FL

Expected to open in 2029, the site will strengthen Novartis' specialized RLT supply chain and manufacturing capabilities.

Carlsbad, CA

Opened in 2025, the Carlsbad site is designed to support current and future RLT demand and is built for expansion.

Indianapolis, IN

Opened in 2024, a site expansion will enable future production of in-house isotopes, critical radioactive components of these therapies.

Millburn, NJ

In 2023, the Millburn site became the first Novartis manufacturing location in the US to produce RLTs.



Cell Therapy Manufacturing

Supporting the timely and coordinated delivery of personalized cell therapies for patients with cancer and immune-related diseases

Morris Plains, NJ

Producing cell therapies since 2015, this site specializes in advanced manufacturing and supply chain processes that ensure timely delivery and quality of these treatments at scale.



Together, these investments support Novartis' ability to **deliver high-quality medicines to US patients** – today and well into the future.